Revolutionizing Early Detection for Smaller Genetic Populations with Our Proprietary AI
Revonco, the only precision cancer screening,
tailored for the people of the Middle East
Read more about our first AI-enabled Liquid Biopsy test
Multi-Cancer Early Detection blood test
Powered by AI and Multiomics
Coming soon
The Most Efficient AI Model for Liquid Biopsy
Introducing Revonco
Detectiome today announced the first version of its flagship Multi-Cancer Early Detection (MCED): Revonco. Revonco is a blood test capable of detecting multiple types of cancer at the earliest stage before the onset of symptoms when the disease can be effectively treated. It offers the first multiomics precision diagnostic test that is specifically designed and optimized for the unique genetic population of the Middle East, providing unparalleled performance.
Early detection saves lives
However, most cancers have no screening method to be detected early.Β Population scale early detection using Detectiome could save up to 2500 lives annually just in the UAE.
One blood test to detect multiple cancers
Why settle for a cancer screening method that only detects one cancer type when you want protection against all?
We understand the impracticality of subjecting individuals to numerous tests for each cancer type. Doctors won't recommend it, patients won't do it, and insurance companies won't cover it.
Life-saving effects of Detectiome vs conventional methods
Of Cancer-related deaths are covered in Detectiome and have a chance of early detection.
VS
Of cancer-related deaths had a chance to use a related screening method only. The rest didn’t have any chance of early detection.
Of Cancer-related deaths are covered in Detectiome and have a chance of early detection.
Survival rate when the cancer is detected at an early asymptomatic stage
VS
Of cancer-related deaths had a chance to use a related screening method only. The rest didn’t have any chance of early detection.
Survival rateΒ when the cancer is detected after symptoms onset
Survival rateΒ when the cancer is detected at an early asymptomatic stage
VS
Survival rateΒ when the cancer is detected after symptoms onset
On the edge of Artificial Intelligence
Our unique and powerful AI model enables product development tailored to local genetic backgrounds.Β
Awards & Media Spotlight
AWARDS
The Most Impactful Startup Award | Mohammed Bin Rashid Innovation Fund
Arman Vali, co-founder, Detectiome, was presented ,the Most Impactful Business award by Tala Al Jabri, angel investor and Board Member, MEVCA. Source: Entrepreneur Middle East/Alexander Bungas
AWARDS
Healthtech
Startup of the year
We're thrilled to announce that Detectiome has been awarded the Healthtech Startup of the Year by Entrepreneur Magazine at the Enterprise Agility Awards 2022. This recognition is a testament to our team's dedication to improving cancer detection through innovative technologies.
In the MEDIA
Startup Spotlight: UAE-Based Detectiome Is Addressing Multiple Pain Points For Patients
With Its Flagship Multi Cancer Early Detection Tool Detectiome aims to address a number of issues, the first of which is the late detection of cancers, which is often when the disease has reached a terminal stage.
In the MEDIA
The Middle Eastβs biotech plans are taking shape β & how
Our startup, Detectiome, is now being recognized and featured on FastCompany Middle East's website.
Wanna be a part of the future?
Letβs talk.
Digital Solutions for
Adjust your design through a wide range of theme options in the WordPress Customizer and see the changes instantly.